MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

Search

Smith & Nephew PLC ADR

Open

34.18 1.7

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

33.58

Max

34.12

Schlüsselkennzahlen

By Trading Economics

Einkommen

296M

Verkäufe

3B

KGV

Branchendurchschnitt

29.768

87.826

Dividendenrendite

2.29

Gewinnspanne

9.895

Angestellte

17,000

EBITDA

723M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+6.08% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.29%

2.26%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

14B

Vorheriger Eröffnungskurs

32.48

Vorheriger Schlusskurs

34.18

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Smith & Nephew PLC ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Jan. 2026, 23:11 UTC

Ergebnisse

Samsung Electronics Expects Record Fourth-Quarter Profit Beat

7. Jan. 2026, 22:55 UTC

Wichtige Markttreiber

Defense Stocks Rebound After Trump Says He Wants $1.5 Trillion Military Budget in 2027

7. Jan. 2026, 21:39 UTC

Wichtige Markttreiber

Raytheon Down Following Trump Post Criticizing Company

7. Jan. 2026, 20:13 UTC

Wichtige Markttreiber

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

7. Jan. 2026, 20:03 UTC

Wichtige Markttreiber

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Executive Pay

7. Jan. 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Jan. 2026, 23:46 UTC

Market Talk

Nikkei May Decline as China-Japan Tensions Linger -- Market Talk

7. Jan. 2026, 23:42 UTC

Akquisitionen, Fusionen, Übernahmen

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 5th Update

7. Jan. 2026, 23:34 UTC

Market Talk

Gold Edges Higher Amid Lingering Geopolitical Risks -- Market Talk

7. Jan. 2026, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

Constellation Closes Deal for Calpine, Creating Biggest Electricity Generator -- Barrons.com

7. Jan. 2026, 22:48 UTC

Market Talk

Infratil's Discount to Net Asset Value Too Good to Ignore -- Market Talk

7. Jan. 2026, 22:46 UTC

Ergebnisse

Samsung Electronics Estimates 2025 Rev KRW332.770T Vs KRW300.870T >005930.SE

7. Jan. 2026, 22:45 UTC

Ergebnisse

Samsung Electronics Estimates 2025 Oper Pft KRW43.530T Vs KRW32.730T >005930.SE

7. Jan. 2026, 22:43 UTC

Akquisitionen, Fusionen, Übernahmen

Revolution Medicines Draws Takeover Interest -- 2nd Update

7. Jan. 2026, 22:42 UTC

Ergebnisse

Samsung Electronics 4Q Oper Pft Estimate Beat FactSet-Compiled Consensus Forecast

7. Jan. 2026, 22:41 UTC

Ergebnisse

Samsung Electronics Sees 4Q Oper Pft KRW20.000T Vs KRW6.490T >005930.SE

7. Jan. 2026, 22:41 UTC

Ergebnisse

Samsung Electronics Sees 4Q Rev KRW93.000T Vs KRW75.790T >005930.SE

7. Jan. 2026, 22:40 UTC

Wichtige Markttreiber

Defense Stocks Rebound After Trump Says He Wants $1.5T Military Budget in 2027

7. Jan. 2026, 22:31 UTC

Market Talk

Macro Tailwinds Strengthen for Chalice Mining -- Market Talk

7. Jan. 2026, 22:22 UTC

Market Talk

Northern Star's Run of Disruptions Increasingly a Concern -- Market Talk

7. Jan. 2026, 22:01 UTC

Market Talk

Valuations of New Zealand Property Stocks Supportive -- Market Talk

7. Jan. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. Jan. 2026, 21:46 UTC

Market Talk

Northern Star's Revised Guidance Looks Achievable -- Market Talk

7. Jan. 2026, 21:22 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly to Buy Ventyx Biosciences for $14 a Share >LLY VTYX

7. Jan. 2026, 21:18 UTC

Akquisitionen, Fusionen, Übernahmen

Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-mediated Diseases >LLY VTYX

7. Jan. 2026, 21:05 UTC

Akquisitionen, Fusionen, Übernahmen

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 4th Update

7. Jan. 2026, 20:29 UTC

Akquisitionen, Fusionen, Übernahmen

AbbVie Near Deal for Revolution Medicines -- Update

7. Jan. 2026, 20:27 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

7. Jan. 2026, 19:58 UTC

Market Talk

Oil Falls As U.S. to Receive Sanctioned Venezuelan Crude -- Market Talk

7. Jan. 2026, 19:48 UTC

Wichtige Markttreiber

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Exec Pay

Peer-Vergleich

Kursveränderung

Smith & Nephew PLC ADR Prognose

Kursziel

By TipRanks

6.08% Vorteil

12-Monats-Prognose

Durchschnitt 35.75 USD  6.08%

Hoch 37.5 USD

Tief 34 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Smith & Nephew PLC ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

2 ratings

0

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

26.64 / 28.37Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat